Drugs / AZD0516
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07181161 | Oct 2025 → Jan 2029 expected | metastatic prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0516 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07181161 ↗ |
| Route | Intravenous | “AZD0516 will be administered via intravenous infusion.” NCT07181161 ↗ |